Optimized enzyme-linked immunosorbent assay for detecting cytomegalovirus infections during clinical trials of recombinant vaccines

Cytomegalovirus (CMV) [1] is a major cause of congenital infection and is currently the most common nongenetic cause of childhood hearing loss [1]. Congenital CMV infection is also an important cause of mental retardation and neuromuscular impairments and was identified as a high priority target in Institute of Medicine vaccine prioritization reports [2]. A vaccine administered to adolescents or adult women could prevent congenital CMV infection by making them immune prior to pregnancy [1]. Since CMV infections in healthy children and adults are rarely clinically apparent, it is necessary to use serodiagnostic tests to detect infections in clinical trial participants as was done in recent phase II clinical trials of a recombinant CMV glycoprotein B (gB) vaccine [3 –6].

Source: Journal of Clinical Virology - October 9, 2017 Category: Virology Authors: Anke Pagnon, Fabienne Piras, Sophie Gimenez-Fourage, Joseline Dubayle, Nad ège Arnaud-Barbe, Catherine Hessler, Catherine Caillet Tags: Full length article Source Type: research